Impaired lesion detectability on gadoxetic acid-enhanced MR imaging in indocyanine green excretory defect: case series of three patients.
Aged
Bile Ducts
/ diagnostic imaging
Coloring Agents
/ pharmacokinetics
Contrast Media
Gadolinium DTPA
Hepatocytes
/ metabolism
Humans
Indocyanine Green
/ pharmacokinetics
Liver
/ diagnostic imaging
Liver-Specific Organic Anion Transporter 1
/ metabolism
Magnetic Resonance Imaging
Male
Middle Aged
Solute Carrier Organic Anion Transporter Family Member 1B3
/ metabolism
Gadoxetic acid
Indocyanine green
Liver diseases
Magnetic resonance imaging
Organic anion transporters
Journal
Japanese journal of radiology
ISSN: 1867-108X
Titre abrégé: Jpn J Radiol
Pays: Japan
ID NLM: 101490689
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
15
01
2020
accepted:
13
05
2020
pubmed:
28
5
2020
medline:
18
3
2021
entrez:
28
5
2020
Statut:
ppublish
Résumé
Indocyanine green (ICG) excretory defect is characterized by an ICG retention rate of more than 50% at 15 min without any other abnormal liver functions. The incidence of ICG excretory defect is 0.007% in the Japanese population. Due to its rarity, the imaging characteristics associated with ICG excretory defect remain unclear. Herein, we present three cases of ICG excretory defect, which showed impaired lesion detectability on gadoxetic acid-enhanced MR imaging (EOB-MRI). In the hepatobiliary phase (HBP) of EOB-MRI, diminished enhancement of the liver parenchyma, prolonged intravascular enhancement, and attenuated gadoxetic acid excretion to the bile duct were observed. Our study also investigated the expression level of organic anion transporting polypeptide (OATP) 1B3 and OATP1B1/1B3, which is related to the uptake of ICG and gadoxetic acid into hepatocytes. All cases showed decreased expression of OATP1B3, which was assumed to be characteristic of ICG excretory defect. The present study indicates that, when patients with ICG excretory defect are evaluated using EOB-MRI, attention should be paid to the impaired lesion detectability in the HBP due to the attenuated gadoxetic acid uptake into the liver parenchyma.
Identifiants
pubmed: 32458127
doi: 10.1007/s11604-020-00991-9
pii: 10.1007/s11604-020-00991-9
doi:
Substances chimiques
Coloring Agents
0
Contrast Media
0
Liver-Specific Organic Anion Transporter 1
0
SLCO1B1 protein, human
0
SLCO1B3 protein, human
0
Solute Carrier Organic Anion Transporter Family Member 1B3
0
gadolinium ethoxybenzyl DTPA
0
Indocyanine Green
IX6J1063HV
Gadolinium DTPA
K2I13DR72L
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
997-1003Références
Tanimoto A, Lee JM, Murakami T, Huppertz A, Kudo M, Grazioli L. Consensus report of the 2nd international forum for liver MRI. Eur Radiol. 2009;19(Suppl 5):S975–89.
doi: 10.1007/s00330-009-1624-y
Huppertz A, Balzer T, Blakeborough A, Breuer J, Giovagnoni A, Heinz-Peer G, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology. 2004;230:266–75.
doi: 10.1148/radiol.2301020269
Tsurusaki M, Sofue K, Murakami T. Current evidence for the diagnostic value of gadoxetic acid-enhanced magnetic resonance imaging for liver metastasis. Hepatol Res. 2016;46:853–61.
doi: 10.1111/hepr.12646
Motosugi U, Ichikawa T, Sou H, Sano K, Tominaga L, Kitamura T, et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging. 2009;30:1042–6.
doi: 10.1002/jmri.21956
Ryeom HK, Kim SH, Kim JY, Kim HJ, Lee JM, Chang YM, et al. Quantitative evaluation of liver function with MRI using Gd-EOB-DTPA. Korean J Radiol. 2004;5:231–9.
doi: 10.3348/kjr.2004.5.4.231
Kumazawa K, Edamoto Y, Yanase M, Nakayama T. Liver analysis using gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging: correlation with histological grading and quantitative liver evaluation prior to hepatectomy. Hepatol Res. 2012;42:1081–8.
doi: 10.1111/j.1872-034X.2012.01027.x
Okuda K, Ohkubo H, Musha H, Kotoda K, Abe H, Tanikawa K. Marked delay in indocyanine green plasma clearance with a near-normal bromosulphophthalein retention test: a constitutional abnormality? Gut. 1976;17:588–94.
doi: 10.1136/gut.17.8.588
Namihisa T, Nambu M, Kobayashi N, Kuroda H. Nine cases with marked retention of indocyanine green test and normal sulfobromophthalein test without abnormal liver histology: constitutional indocyanine green excretory defect. Hepatogastroenterology. 1981;28:6–12.
pubmed: 7216141
Nambu M, Namihisa T. Hepatic transport of serum bilirubin, bromsulfophthalein, and indocyanine green in patients with congenital non-hemolytic hyperbilirubinemia and patients with constitutional indocyanine green excretory defect. J Gastroenterol. 1996;31:228–36.
doi: 10.1007/BF02389522
de Graaf W, Hausler S, Heger M, van Ginhoven TM, van Cappellen G, Bennink RJ, et al. Transporters involved in the hepatic uptake of (99 m)Tc-mebrofenin and indocyanine green. J Hepatol. 2011;54:738–45.
doi: 10.1016/j.jhep.2010.07.047
Kitao A, Matsui O, Yoneda N, Kozaka K, Shinmura R, Koda W, et al. The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol. 2011;21:2056–66.
doi: 10.1007/s00330-011-2165-8
Kitao A, Zen Y, Matsui O, Gabata T, Kobayashi S, Koda W, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging–correlation with molecular transporters and histopathologic features. Radiology. 2010;256:817–26.
doi: 10.1148/radiol.10092214
Nakamura Y, Date S, Toyota N, Tani C, Honda Y, Komoto D, et al. Effect of lapatinib on hepatic parenchymal enhancement on gadoxetate disodium (EOB)-enhanced MRI scans. J Comput Assist Tomogr. 2011;35:351–2.
doi: 10.1097/RCT.0b013e31821a02aa
Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158:693–705.
doi: 10.1111/j.1476-5381.2009.00430.x
Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos. 2005;33:434–9.
doi: 10.1124/dmd.104.001909
Sano K, Ichikawa T, Motosugi U, Sou H, Muhi AM, Matsuda M, et al. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology. 2011;261:834–44.
doi: 10.1148/radiol.11101840
Imada S, Kobayashi T, Kitao A, Matsui O, Hashimoto M, Ide K, et al. Central bisectionectomy for hepatocellular carcinoma in a patient with indocyanine green excretory defect associated with reduced expression of the liver transporter. Surg Case Rep. 2016;2:89.
doi: 10.1186/s40792-016-0216-8
Nassif A, Jia J, Keiser M, Oswald S, Modess C, Nagel S, et al. Visualization of hepatic uptake transporter function in healthy subjects by using gadoxetic acid-enhanced MR imaging. Radiology. 2012;264:741–50.
doi: 10.1148/radiol.12112061
Yoneda N, Matsui O, Ikeno H, Inoue D, Yoshida K, Kitao A, et al. Correlation between Gd-EOB-DTPA-enhanced MR imaging findings and OATP1B3 expression in chemotherapy-associated sinusoidal obstruction syndrome. Abdom Imaging. 2015;40:3099–103.
doi: 10.1007/s00261-015-0503-z
Kimura Y, Sato S, Hitomi E, Ohyama M, Adachi K, Inagaki Y, et al. Coexpression of organic anion-transporting polypeptides 1B3 and multidrug-resistant proteins 2 increases the enhancement effect of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid on hepatocellular carcinoma in magnetic resonance imaging. Hepatol Res. 2014;44:327–37.
doi: 10.1111/hepr.12128
Tsuda N, Matsui O. Cirrhotic rat liver: reference to transporter activity and morphologic changes in bile canaliculi–gadoxetic acid-enhanced MR imaging. Radiology. 2010;256:767–73.
doi: 10.1148/radiol.10092065